Fresenius SE & Co. KGaA · XETR:FRE

Fresenius SE & Co. KGaA — Berenberg and Goldman Sachs German Corporate Conference 2024

64 slides from Fresenius SE & Co. KGaA's conference presentation, Sep 24, 2024

  1. Slide 1: #FutureFresenius

    #FutureFresenius Berenberg and Goldman Sachs German Corporate Conference September 24, 2024 – Munich

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive

  3. Slide 3: Agenda

    01 Company overview Financial priorities & outlook 04 02 Strategy Attachments 05 03 Business update Q2/24

  4. Slide 4: Company overview

    Company overview 01 01 Strategy 02 Company overview Business update Q2/24 03 Financial priorities & outlook 04 Attachments 05

  5. Slide 5: This is Fresenius

    This is Fresenius OUR MISSION We save and improve human lives with affordable, accessible and innovative healthcare products and highest quality in clinical care OUR VISION We are the trusted, market-leading healthcare company that unites cutting-edge technology and human care to shape next-level th

  6. Slide 6: Healthcare: Strong needs underpinning secular sector growth

    Ageing global population +40% to 1.4B people >60 years worldwide by 2030 1 Increasing healthcare spend Health expenditures rise to >10% of global GDP by 2030 2 Higher prevalence of chronic diseases 84% of 67M deaths globally in 2030 due to chronic diseases 3 Demand for health workforce Healthcare: 1

  7. Slide 7: Committed to Life

    Committed to Life Employing and developing 40,000 nurses Berenberg and Goldman Sachs German Corporate Conference, September 24, 2024 © Fresenius SE & Co. KGaA Investor Relations 7

  8. Slide 8: Simpler and focused

    Simpler and focused Fresenius Kabi Fresenius Helios Pharma Biopharma Nutrition MedTech (Bio)Pharma platform MedTech platform Care provision platform Berenberg and Goldman Sachs German Corporate Conference, September 24, 2024 © Fresenius SE & Co. KGaA Investor Relations 8

  9. Slide 9: Fresenius Kabi: Strong relevance and scale across business units

    Fresenius Kabi Strong relevance and scale across our 4 business units Pharma Nutrition MedTech Biopharma Hospital-sold generic IV Enteral and Parenteral Stationary drug delivery AIID & oncology biologic Overview Drugs and Fluids Nutrition products and therapy devices drugs (biosimilars) #1 global IV

  10. Slide 10: Fresenius Helios: leading hospital care provider in Germany and Spain

    Fresenius Helios We are the leading hospital care provider in Germany and Spain GERMANY SPAIN 80+ 57 #1 hospital provider #1 private hospital provider hospitals (~6% market share) (~12% market share1) hospitals Position 89% 1st Share of cases with better Hospital group globally to receive performanc

  11. Slide 11: Fresenius share & shareholder structure

    Fresenius share & shareholder structure Share price development LTM (%) Analyst recommendations (%) Click to view our interactive share price tool Click to view downloadable set of the consensus data 130 FRE 18 120 Accumulate/Add/buy/Outperform/Overeight 110 DAX Equal-weight/Hold/Neutral 100 STOXX 9

  12. Slide 12: Progressive dividend policy

    Progressive dividend policy Dividend Payout ratio1 Commitment to delivering attractive and predictable shareholder 24% 24% 27% 28% 30% return At least €0.92 €0.92 stable €0.88 €0.84 €0.75 Dividend to grow in line with EPS cc growth, but at least stay on prior year level Due to legal restrictions res

  13. Slide 13: Strategy

    Company overview 01 02 Strategy 02 Strategy Business update Q2/24 03 Financial priorities & outlook 04 Attachments 05

  14. Slide 14: Becoming a therapy-focused healthcare company

    #FutureFresenius Becoming a therapy-focused healthcare company Global value pool1 Specialized Leverage at-scale capabilities (Bio)pharma and capacities for leading (bio-) platform pharmaceutical & nutrition products €350–450bn Targeted Empower cutting-edge medical MedTech technology solutions in cri

  15. Slide 15: Unique set-up of mutually reinforcing healthcare platforms

    Unique set-up of mutually reinforcing healthcare platforms 30+ studies in parenteral Breakthrough technology and enteral nutrition infusion system Multi-faceted Health Equity Device supplier for 1/3rd of 3 multiproduct biologic drug FDA/EMA-approved CAR-T cell therapies substance facilities #2 for p

  16. Slide 16: Addressing the driving forces of tomorrow's healthcare

    Addressing the driving forces of tomorrow's healthcare Multi-faceted Integrated health equity therapies Securing broad access Enabling targeted and and affordable healthcare multimodal treatment options Human-to- AI-powered human care clinical decisions Executing end-to-end Supporting efficient, cli

  17. Slide 17: RESET delivered, now focusing on REVITALIZE

    #FutureFresenius RESET delivered, now focusing on REVITALIZE Deconsolidation of FMC completed Dynamic financial progression Structural simplification Sharpen focus Strategic portfolio measures concluded Deleveraging continues Accelerate performance Berenberg and Goldman Sachs German Corporate Confer

  18. Slide 18: Operating Companies set up for value-accretive growth

    Operating Companies set up for value-accretive growth F³ - Fresenius Financial Framework F³ ambitions EBIT margin 14 – 17% 10 – 12% geared for substantial earnings Organic revenue 4 – 7% 4 – 6% growth growth CAPITAL EFFICIENCY ROIC CAPITAL STRUCTURE CASH CCR1 Strong balance Leverage ratio 6 - 8% 3.0

  19. Slide 19: Re-VITALIZE: Kabi 3+1 strategy delivering

    Re-VITALIZE Kabi 3+1 strategy delivering Growth & margin ambitions 3 1 Biopharma MedTech Nutrition Pharma 3-4× €2.4bn €3.8bn €1.4bn 4-7% 2-4% 8-10% €0.2bn p.a.1 p.a.1 p.a.1 2022 Revenue 2022 sales 2026 Ambition 2026 ambition 2022 2022Revenue sales 2026 Ambition 2026 ambition 2022 2022Revenue sales 2

  20. Slide 20: Fresenius Kabi securing critical drug supplies globally

    Fresenius Kabi securing critical drug supplies globally Largest IV Generics Portfolio in the market Distinct market Leader for IV Fluids # of products in portfolio EU Infusion Solutions Market ~170 Volume Share distribution #2 Others #3 #4 #5 #3 #6 #7 #8 #2 Continuously adding new products EU Irriga

  21. Slide 21: Attractive biosimilar portfolio and pipeline

    Attractive biosimilar portfolio and pipeline focused on oncology and autoimmune diseases Candidate & TA Pre-clinical Clinical trials Approval Launch Adalimumab EU: Apr 2019 / US: Dec 2022 EU: May 2019 / US: Jul 2023 Autoimmune Pegfilgrastim FRESENIUS KABI EU: Mar 2022 / US: Sep 2022 EU PFS: Oct 2022

  22. Slide 22: Re-VITALIZE: Helios value creation plan

    Re-VITALIZE Helios value creation plan Growth ambitions (Revenue1 in €bn) Value creation levers 4-6% p.a. Extend medical cluster & specialization strategy (org.) Further improve outpatient integration 7.0 7.3 2022 2023 2027 Earnings growth ≥ ambition revenue growth Further boost emergency care provi

  23. Slide 23: Our sustainability ambition: Taking care of people and planet

    Our sustainability ambition: Taking care of people and planet ▪ We aim to ensure patient well-being, to be employer of choice and to create sustainable value for our company and the communities in which we operate ▪ We focus on: o Providing excellent quality of our products and services – from human

  24. Slide 24: #FutureFresenius: Reset, Revitalize, Rejuvenate, Reimagine

    #FutureFresenius REIMAGINE REJUVENATE Shape the future of healthcare REVITALIZE Pursue platform-driven growth opportunities Optimize portfolio & RESET refine operating model Focus + Simplification + Performance = VALUE Berenberg and Goldman Sachs German Corporate Conference, September 24, 2024 © Fre

  25. Slide 25: Accelerating performance in 2024

    #FutureFresenius Accelerating performance in 2024 Operating Company focus Accelerated earnings growth OpCo consistent strong performance Cost programs extended Costs out Debt reduction a priority Structures simplified Invigorated innovation Stronger management team Over-delivered Re-VITALIZE Berenbe

  26. Slide 26: Delivering on our promises and driving change

    #FutureFresenius Delivering on our promises and driving change 2024 – Strong performance, improved growth momentum Net Debt/EBITDA at 3.43 in Q2/24; entering target range Drive down leverage 3.0 to 3.5x; further improvement expected until year-end Already ~€68m incremental cost savings of expected R

  27. Slide 27: Business update Q2/24

    Company overview 01 03 Strategy 02 Business update Business update Q2/24 03 Q2/24 Financial priorities & outlook 04 Attachments 05

  28. Slide 28: Dynamic financial progression as transformation gains momentum

    Dynamic financial progression as transformation gains momentum FY/20 FY/21 FY/22 FY/23 H1/24 EPS1 EPS growth back to solid yoy positive growth trajectory -3% +5% -13% -15% +10%2 1 Before special items; at constant currency 2 Growth rates adjusted for Argentina hyperinflation Berenberg and Goldman Sa

  29. Slide 29: Q2/24 Excellent financial performance

    Q2/24 Excellent financial performance Strong revenue growth underpinning continued momentum €5.4bn €660m €388m Excellent EBIT growth of 15%2 reflects the strong performance of Kabi and Helios +8% org.1 +15%2 +15%2 EPS increased by 15% demonstrating bottom-line delivery Revenue EBIT Net income excl.

  30. Slide 30: Fresenius Kabi: Growth Vectors accelerate

    Fresenius Kabi Growth Vectors accelerate, fueling performance Quarterly financials Main developments 2,200 Excellent organic revenue growth of 11 %1 above top-end of structural growth band, helped by pricing effects in Argentina 15.9% 2,100 15.1% Growth Vectors with very strong 19 %1 organic 14.2% 1

  31. Slide 31: Fresenius Helios: Strong financial performance driven by Helios Spain

    Fresenius Helios Strong financial performance driven by Helios Spain Quarterly financials Main developments 3,300 Strong organic revenue growth at top-end of 3,200 structural growth band, helped by Easter effect in 11.5% 11.0% 11.1% Spain (11% organic growth); Solid 3% organic 10.0% EBIT revenue gro

  32. Slide 32: Excellent operating cash flow development in Q2/24

    Excellent operating cash flow development in Q2/24 €m Q2/24 Q2/23 Q1/24 Q2/24 LTM OCF significantly improved; both yoy and sequentially OCF 709 148 -28 2,559 Kabi: strong OCF development thereof Kabi 259 180 157 1,230 driven by improved Working Capital thereof Helios 604 61 -117 1,562 Helios: Strong

  33. Slide 33: Financial priorities & outlook

    Company overview 01 04 Strategy 02 Financial priorities Business update Q2/24 03 & outlook Financial priorities & outlook 04 Attachments 05

  34. Slide 34: FY/24: Focus on execution

    FY/24: Focus on execution 1 More cost savings 2 Drive down leverage 3 Rigorous focus on capital efficiency and returns Re-VITALIZE Berenberg and Goldman Sachs German Corporate Conference, September 24, 2024 © Fresenius SE & Co. KGaA Investor Relations 34

  35. Slide 35: Cost and productivity savings ahead of plan

    1 Cost and productivity savings ahead of plan Cost savings ~ 400 EBIT view, cumulated €m Over-delivered in H1/24: 336 350 • Savings driven by complexity 330 reductions, supply chain 282 optimization and procurement improvements • Majority realized by Kabi 158 Ambition to achieve 2025 savings target

  36. Slide 36: Deleveraging continues: Entering leverage target corridor

    2 Deleveraging continues: Entering leverage target corridor Robust operational execution and performance Structural productivity improvements Disciplined and stringent capital allocation Greater cash focus across the Group Further Energy relief related dividend suspension for FY/23 deleveraging Vame

  37. Slide 37: ROIC improvements to drive value creation

    3 ROIC improvements to drive value creation Targeted and disciplined capital allocation Strong underlying growth at Kabi and Helios Focused investments along strategic growth pillars and portfolio optimization Improved structural Operating Invested productivity and efficiency Performance Capital Dec

  38. Slide 38: Outlook for FY/24 confirmed

    Outlook for FY/24 confirmed: Optimistic to get into upper half of EBIT growth range FY/23 base1 FY/24 outlook €8,009m Mid to high single-digit organic revenue growth Revenue growth (organic): Fresenius 4–7% growth Kabi €1,145m Between 15–16% EBIT margin; 2023: €20,307m1 structural EBIT margin band o

  39. Slide 39: Our sustainability ambition: We measure what we care for

    Our sustainability ambition: We measure what we care for Committed to Life Human Dimension Planet Dimension Excellent Human-to-Human Care Healthy Planet Leading Medical Outcomes Employee Engagement Decarbonization Future Action Helios ≥88% 4.33 Net zero We develop a holistic approach to a healthy pl

  40. Slide 40: Attachments

    Company overview 01 05 Strategy 02 Attachments Business update Q2/24 03 Financial priorities & outlook 04 Attachments 05

  41. Slide 41: Guidance base

    Guidance base Portfolio Base for FY/2023 Vamed €m Adjustments Guidance Actual Exit Helios FY/24 Revenue 8,009 8,009 EBIT 1,145 1,145 Revenue 12,320 -368 11,952 EBIT 1,232 -42 1,190 Revenue 2,356 -2,356 0 EBIT -16 +16 0 Revenue -386 +732 346 Corporate EBIT -99 +30 -69 Revenue 22,299 -368 -1,624 20,30

  42. Slide 42: FY/24 Fresenius Group Other financial KPIs

    FY/24 Fresenius Group Other financial KPIs €m FY/23 FY/24 expectation Interest expense €418m €420 to €440m Profitability Tax rate 28.3% Between 25 to 26% CAPEX % of revenue 5.1% Around 5% Capital CCR LTM 1.0 Around 1 Allocation ROIC 5.2% Around 6% (previous: in the range of 5.4 to 6.0%) Leverage rat

  43. Slide 43: Financial & accounting implications of Vamed exit I

    FY/24 Fresenius Group Financial & accounting implications of Vamed exit I STRUCTURE REHABILITATION ▪ 67% to be divested, 33% to remain with FSE DIVESTED HFO1 | ~40%2 of revenue ▪ Closing expected in H2/24 ▪ Discontinued operations reported as special items ▪ Closing expected in H2/24 AUSTRIA OPERATI

  44. Slide 44: Financial & accounting implications of Vamed exit II

    FY/24 Fresenius Group Financial & accounting implications of Vamed exit II PROFIT & LOSS CASH FLOW REHABILITATION ▪ Special items of €427 million as per Q2/24 DIVESTED HFO1 | ~40%2 of revenue ▪ No cash impact ▪ Divested Rehabilitation stake (67%) to be reported as discontinued operations until closi

  45. Slide 45: Capital efficiency and returns – deleveraging remains key

    Capital efficiency and returns – deleveraging remains key ROIC1 C C R 1,2 N E T D E B T / E BI T D A 1, 3 10% 2,2 2.2 4,5 xx 4.5 4.19 9% 1,9 1.9 4.03 8% 4,0 xx 4.0 3.76 1,6 1.6 3.96 3.75 7% 3.80 1,3 1.3 3.43 6% 3,5 xx 3.5 6.0 1,0 1.0 5% 5.6 1.1 5.2 5.5 1.0 1.0 5.0 5.0 5.2 0,7 0.7 0.9 0.9 0.9 0.9 4%

  46. Slide 46: Q2/24 Fresenius Group Statement of Income

    Q2/24 Fresenius Group Statement of Income (Summary, unaudited) €m Q2/24 Q2/23 restated Q2/23 previous Growth2 Revenue 5,460 5,245 10,359 4% Cost of revenue -4,237 -4,141 -8,026 -2% Gross profit 1,223 1,104 2,333 11% Selling, general, and administrative expenses -803 -773 -1,589 -4% Research and deve

  47. Slide 47: H1/24 Fresenius Group Statement of Income

    H1/24 Fresenius Group Statement of Income (Summary, unaudited) €m H1/24 H1/23 restated H1/23 previous Growth2 Revenue 10,837 10,504 20,584 3% Cost of revenue -8,237 -8,072 -15,740 -2% Gross profit 2,600 2,432 4,844 7% Selling, general, and administrative expenses -1,485 -1,437 -3,115 -3% Research an

  48. Slide 48: Q2/24 Fresenius Group Reconciliation

    Q2/24 Fresenius Group Reconciliation €m Q2/24 Q2/23 Growth Growth cc Revenue reported 5,460 5,245 4% 6% Divestitures Eugin and clinic Peru - -93 Vamed exit -46 -39 Revenue (before special items) 5,414 5,113 6% 8% EBIT reported (after special items) 265 187 42% 41% Divestitures Eugin and clinic Peru

  49. Slide 49: H1/24 Fresenius Group Reconciliation

    H1/24 Fresenius Group Reconciliation €m H1/24 H1/23 Growth Growth cc Revenue reported 10,837 10,504 3% 5% Divestitures Eugin and clinic Peru -30 -182 Vamed exit -110 -158 Revenue (before special items) 10,697 10,164 5% 7% EBIT reported (after special items) 821 708 16% 16% Divestitures Eugin and cli

  50. Slide 50: Q2/24 Fresenius Group Revenue

    Q2/24 Fresenius Group Revenue Revenue by Region Revenue by Business Segment in % in % 7 1 1 8 39 12 €5.4 bn €5.4 bn 60 72 Europe North America Asia-Pacific Latin America & Others Fresenius Kabi Fresenius Helios Corporate/Other Africa Berenberg and Goldman Sachs German Corporate Conference, September

  51. Slide 51: H1/24 Fresenius Group Revenue

    H1/24 Fresenius Group Revenue Revenue by Region Revenue by Business Segment in % in % 7 1 1 7 39 12 €10.7 bn €10.7 bn 60 73 Europe North America Asia-Pacific Latin America & Others Fresenius Kabi Fresenius Helios Corporate/Other Africa Berenberg and Goldman Sachs German Corporate Conference, Septemb

  52. Slide 52: Q2/24 Revenue by Business Segment – FX, Acquisitions/Divestitures

    Q2/24 Revenue by Business Segment – FX, Acquisitions/Divestitures Growth at Currency Growth at actual translation constant Organic Acquisi- Divestiture/ €m Q2/24 Q2/23 rates effects rates growth1 tions Others Fresenius 2,101 2,001 5% -5% 10% 11% 0% -1% Kabi Fresenius 3,230 3,020 7% 1% 6% 6% 0% 0% He

  53. Slide 53: H1/24 Revenue by Business Segment – FX, Acquisitions/Divestitures

    H1/24 Revenue by Business Segment – FX, Acquisitions/Divestitures Growth at Currency Growth at actual translation constant Organic Acquisi- Divestiture/ €m H1/24 H1/23 rates effects rates growth1 tions Others Fresenius 4,152 3,992 4% -5% 9% 10% 0% -1% Kabi Fresenius 6,384 5,997 6% 0% 6% 6% 0% 0% Hel

  54. Slide 54: Fresenius Kabi Organic Revenue Growth by Product Group

    Q2/24 & H1/24 Fresenius Kabi Organic Revenue Growth by Product Group Δ YoY Δ YoY €m Q2/24 organic2 H1/24 organic2 MedTech 389 9% 761 5% Nutrition 610 14% 1,189 11% Biopharma 150 102% 289 109% Growth Vectors1 1,149 19% 2,239 16% Pharma 951 2% 1,913 3% (IV Drugs & Fluids) Corporate 0 -- 0 -- Total rev

  55. Slide 55: Fresenius Kabi EBIT(DA) development

    Q2/24 & H1/24 Fresenius Kabi EBIT(DA) development €m Q2/24 Δ YoY cc2 H1/24 Δ YoY cc2 Total EBITDA 472 18% 912 14% Margin 22.5% +250 bps 22.0% +190 bps Total EBIT 334 17% 644 12% Margin 15.9% +170 bps 15.5% +110 bps Growth Vectors1 169 47% 293 31% Margin 14.7% +640 bps 13.1% +440 bps Pharma 185 -11%

  56. Slide 56: Fresenius Helios Key Financials

    Q2/24 & H1/24 Fresenius Helios Key Financials €m Q2/24 Δ YoY cc H1/24 Δ YoY cc Total revenue 3,230 6%1 6,384 6%1 Thereof Helios Germany 1,882 3%1 3,785 4%1 Thereof Helios Spain 1,348 11%1 2,599 9%1 Total EBIT 357 18% 705 16% Margin 11.1% +110 bps 11.0% +90 bps Thereof Helios Germany 157 2% 362 17% M

  57. Slide 57: Fresenius Helios Key Metrics

    Fresenius Helios Key Metrics H1/24 FY/23 ΔYoY Helios Germany Hospitals 85 86 -1% - Acute care hospitals 82 83 -1% Beds 29,955 29,976 0% - Acute care hospitals 29,389 29,410 0% Admissions 2,702,597 5,470,871 -3% - patients treated in hospital 583,876 1,136,446 3% - patients treated as outpatient 2,11

  58. Slide 58: H1/24 Calculation of Noncontrolling Interests

    H1/24 Fresenius Group Calculation of Noncontrolling Interests €m H1/24 H1/23 Earnings before tax and noncontrolling interests 1,071 966 Taxes -271 -231 Noncontrolling interests, thereof -41 -33 Fresenius Kabi -35 -28 Fresenius Helios -6 -4 Corporate 0 -1 Net income from deconsolidated operations 129

  59. Slide 59: Q2/24 & LTM Fresenius Group Cash Flow

    Q2/24 & Q2/24 LTM Fresenius Group Cash Flow Q2/24 LTM Q2 €m Q2/24 LTM Margin Δ YoY Operating Cash Flow 709 2,559 12.3% -- Capex (net) -147 -968 -4.6% 31% Free Cash Flow 562 1,591 7.7% -- (before acquisitions, dividends, and lease liabilities) Acquisitions (net) 27 -18 Dividends 112 106 Lease liabili

  60. Slide 60: Reconciliation adjusted Free Cash Flow for CCR

    Q2/24 & H1/24 Fresenius Group Reconciliation adjusted Free Cash Flow for CCR €m Q2/24 Q2/23 H1/24 H1/23 Operating Cash Flow 709 148 681 199 Capex (net) -147 -214 -337 -395 Free Cash Flow 562 -66 344 -196 (before acquisitions, dividends, and lease liabilities) Special items +2 +28 +31 +51 (net income

  61. Slide 61: Q2/24 Cash Flow development

    Q2/24 Cash Flow development Operating Cash Flow Capex (net)1 Free Cash Flow2 Q2/24 Q2/23 Q2/24 Q2/23 Q2/24 Q2/23 Q2/24 Q2/23 Q2/24 Q2/23 Q2/24 Q2/23 €m Margin Margin % sales % sales Margin Margin 259 180 12.3% 9.0 -67 -83 -3.2% -4.2% 192 97 9.1% 4.8% 604 61 18.7% 2.0% -74 -125 -2.3% -4.1% 530 -64 16

  62. Slide 62: Q2/24 LTM Cash Flow development

    Q2/24 LTM Cash Flow development Operating Cash Flow Capex (net)1 Free Cash Flow2 Q2/24 Q2/23 Q2/24 Q2/23 Q2/24 Q2/23 Q2/24 Q2/23 Q2/24 Q2/23 Q2/24 Q2/23 €m LTM LTM LTM LTM LTM LTM LTM LTM LTM LTM LTM LTM Margin Margin % sales % sales Margin Margin 1,230 800 15.1% 9.9% -409 -480 -5.0% -5.9% 821 320 1

  63. Slide 63: Financial Calendar / Contact

    Financial Calendar / Contact Financial Calendar Social Media 06 Nov 2024 Results Q3/24 Follow Fresenius Investor Relations on LinkedIn: Events 23 Sep 2024 Baader Investment Conference, Munich 24 Sep 2024 Goldman Sachs & Berenberg German Corporate Conference, Munich 01 Oct 2024 Berenberg Madrid Semin

  64. Slide 64: #FutureFresenius

    #FutureFresenius August 2024

Fresenius SE & Co. KGaA — Berenberg and Goldman Sachs German Corporate Conference 2024 on 6ix